3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          Repeated risk assessments and treatment patterns over long time are sparsely studied in chronic thromboembolic pulmonary hypertension (CTEPH); thus, we aimed to investigate changes in risk status and treatment patterns in incident patients with CTEPH over a 5 year period.

          Methods and results

          Descriptive and explorative study including 311 patients diagnosed with CTEPH 2008–2019 from the Swedish pulmonary hypertension registry, stratified by pulmonary endarterectomy surgery (PEA). Risk and PH‐specific treatment were assessed in surgically treated (PEA) and medically treated (non‐PEA) patients at diagnosis and up to 5 years follow‐up. Data are presented as median (Q1–Q3), count or per cent. Prior to surgery, 63% in the PEA‐group [ n = 98, age 64 (51–71) years, 37% female] used PH‐specific treatment and 20, 69, and 10% were assessed as low, intermediate or high risk, respectively. After 1 year post‐surgery, 34% had no PH‐specific treatment or follow‐up visit registered despite being alive at 5 years. Of patients with a 5 year visit ( n = 23), 46% were at low and 54% at intermediate risk, while 91% used PH‐specific treatment.

          In the non‐PEA group [ n = 213, age 72 (65–77) years, 56% female], 28% were assessed as low, 61% as intermediate and 11% as high risk. All patients at high risk versus 50% at low risk used PH‐specific treatment. The 1 year mortality was 6%, while the risk was unchanged in 57% of the patients; 14% improved from intermediate to low risk, and 1% from high to low risk. At 5 years, 27% had a registered visit and 28% had died. Of patients with a 5 year visit ( n = 58), 38% were at low, 59% at intermediate and 1% at high risk, and 86% used PH‐specific treatment.

          Conclusions

          Risk status assessed pre‐surgery did not foresee long‐term post‐PEA risk and pre‐surgery PH‐specific treatment did not foresee long‐term post‐PEA treatment. Medically treated CTEPH patients tend to remain at the same risk over time, suggesting a need for improved treatment strategies in this group.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: not found
          • Article: not found

          2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Chronic thromboembolic pulmonary hypertension

            Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and a major cause of chronic PH leading to right heart failure and death. Lung ventilation/perfusion scintigraphy is the screening test of choice; a normal scan rules out CTEPH. In the case of an abnormal perfusion scan, a high-quality pulmonary angiogram is necessary to confirm and define the pulmonary vascular involvement and prior to making a treatment decision. PH is confirmed with right heart catheterisation, which is also necessary for treatment determination. In addition to chronic anticoagulation therapy, each patient with CTEPH should receive treatment assessment starting with evaluation for pulmonary endarterectomy, which is the guideline recommended treatment. For technically inoperable cases, PH-targeted medical therapy is recommended (currently riociguat based on the CHEST studies), and balloon pulmonary angioplasty should be considered at a centre experienced with this challenging but potentially effective and complementary intervention.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension.

              Guidelines recommend a goal-oriented treatment approach in pulmonary arterial hypertension (PAH). The aim is to reach a low-risk profile, as determined by a risk assessment instrument. This strategy is incompletely validated. We aimed to investigate the bearing of such risk assessment and the benefit of reaching a low-risk profile.
                Bookmark

                Author and article information

                Contributors
                barbro.kjellstrom@med.lu.se
                Journal
                ESC Heart Fail
                ESC Heart Fail
                10.1002/(ISSN)2055-5822
                EHF2
                ESC Heart Failure
                John Wiley and Sons Inc. (Hoboken )
                2055-5822
                04 July 2022
                October 2022
                : 9
                : 5 ( doiID: 10.1002/ehf2.v9.5 )
                : 3264-3274
                Affiliations
                [ 1 ] Lund University, Department of Clinical Sciences Lund Clinical Physiology and Skåne University Hospital Lund Sweden
                [ 2 ] Cardiology Unit, Department of Medicine Karolinska Institutet Stockholm Sweden
                [ 3 ] Department of Clinical Sciences Lund, Cardiology Lund University Lund Sweden
                [ 4 ] Department of Cardiology University Hospital Uppsala Sweden
                [ 5 ] Actelion Pharmaceuticals Allschwil Switzerland
                [ 6 ] Department of Clinical Sciences Lund, Section for Rheumatology Lund University and Skåne university hospital Lund Sweden
                [ 7 ] Department of Cardiology and Department of Clinical Physiology Institution of Medicine and Health Science Linköping University Linköping Sweden
                [ 8 ] Lung Unit, Department of Medicine Karolinska Institutet and Karolinska University Hospital Stockholm Sweden
                [ 9 ] The Haemodynamic Lab, The Section for Heart Failure and Valvular Disease, VO. Heart and Lung Medicine Skåne University Hospital Lund Sweden
                [ 10 ] Janssen Cilag AB Solna Sweden
                [ 11 ] Pediatric Heart Center, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, and Department of Pediatrics, Institute for Clinical Sciences, Sahlgrenska Academy University of Gothenburg Gothenburg Sweden
                [ 12 ] Department of Cardiology, Sahlgrenska Academy University of Gothenburg and Sahlgrenska University Hospital Gothenburg Sweden
                [ 13 ] Department of Public Health and Clinical Medicine, Medicine Unit Umeå University Umeå Sweden
                Author notes
                [*] [* ]Correspondence to: Barbro Kjellström, Lund University, Department of Clinical Sciences Lund, Clinical Physiology and Skåne University Hospital, Lund, Sweden. Email: barbro.kjellstrom@ 123456med.lu.se
                Author information
                https://orcid.org/0000-0002-7936-1209
                https://orcid.org/0000-0001-6794-2201
                https://orcid.org/0000-0002-8965-4785
                https://orcid.org/0000-0003-4919-2771
                https://orcid.org/0000-0002-4753-3811
                https://orcid.org/0000-0002-2395-8989
                Article
                EHF214033 ESCHF-22-00072
                10.1002/ehf2.14033
                9715829
                35789127
                9cc325ea-9856-4cf6-85cf-816b51740ed3
                © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 20 April 2022
                : 26 January 2022
                : 03 June 2022
                Page count
                Figures: 3, Tables: 2, Pages: 11, Words: 4601
                Funding
                Funded by: Actelion Pharmaceuticals , doi 10.13039/100005646;
                Funded by: Swedish Association of Local Authorities and Regions , doi 10.13039/501100009240;
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                October 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.1 mode:remove_FC converted:01.12.2022

                pulmonary hypertension,pulmonary endarterectomy,risk assessment

                Comments

                Comment on this article